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Abstract
Anaplastic large cell lymphoma (ALCL) is a rare, aggressive, non-Hodgkin’s lymphoma that is characterized by CD30
expression and disease onset in young patients. About half of ALCL patients bear the t(2;5)(p23;q35) translocation,
which results in the formation of the nucleophosmin-anaplastic lymphoma tyrosine kinase (NPM–ALK) fusion
protein (ALCL ALK+). However, little is known about the molecular features and tumour drivers in ALK-negative
ALCL (ALCL ALK−), which is characterized by a worse prognosis. We found that ALCL ALK−, in contrast to ALCL
ALK+, lymphomas display high miR-155 expression. Consistent with this, we observed an inverse correlation
between miR-155 promoter methylation and miR-155 expression in ALCL. However, no direct effect of the ALK
kinase on miR-155 levels was observed. Ago2 immunoprecipitation revealed miR-155 as the most abundant miRNA,
and enrichment of target mRNAs C/EBP𝛃 and SOCS1. To investigate its function, we over-expressed miR-155 in
ALCL ALK+ cell lines and demonstrated reduced levels of C/EBP𝛃 and SOCS1. In murine engraftment models of
ALCL ALK−, we showed that anti-miR-155 mimics are able to reduce tumour growth. This goes hand-in-hand
with increased levels of cleaved caspase-3 and high SOCS1 in these tumours, which leads to suppression of STAT3
signalling. Moreover, miR-155 induces IL-22 expression and suppresses the C/EBP𝛃 target IL-8. These data suggest
that miR-155 can act as a tumour driver in ALCL ALK− and blocking miR-155 could be therapeutically relevant.
Original miRNA array data are to be found in the supplementary material (Table S1).
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Anaplastic large cell lymphoma (ALCL) is an aggres-
sive non-Hodgkin’s T cell lymphoma (NHL) that occurs
mostly in children but also in adults. The majority
of patients bear the typical t(2;5) aberration, which
leads to fusion of the N-terminal oligomerization
domain of nucleophosmin (NPM) to the cytoplasmic
portion of the anaplastic lymphoma kinase receptor
tyrosine kinase (ALK) [1,2]. This results in dimer-
ization and constitutive activation of the kinase and
its downstream effectors, including PI3K–AKT [3],
JAK3–STAT3 [4,5], MAPK–ERK [6–8], PDGFRB
[9] and PLC–PKC [10]. The transforming capac-
ity of nucleophosmin-anaplastic lymphoma kinase
(NPM–ALK) has been demonstrated in vitro, leading
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to anchorage-independent growth [11,12], and in vivo
in diverse engraftment and transgenic mouse models
[13–17]. However, not much is known about oncogenic
drivers in ALCL without ALK translocations (ALCL
ALK−), a lymphoma that has a worse prognosis than
ALCL ALK+ [18]. Despite this relevant difference in
clinical outcome, the morphology and gene expression
profiles of ALCL are remarkably independent of the
presence or absence of the ALK translocation, and only
a gene classifier, but no single genes except the ALK
kinase, are able to distinguish between the two entities
[19–22]. Therefore, the WHO classification published
in 2008 provisionally defines ALCL with and without
the ALK translocation as two different disease entities,
mainly based on the diverging clinical course [23].
However, with better technologies and a deeper exam-
ination of the genome, transcriptome and epigenome,
some differences between ALCL ALK+ and ALK−
have begun to emerge. At the genomic level, deep
sequencing identified the t(6;7)(p25.3;q32.3) transloca-
tion in 18% of ALCL ALK− patients [24]. More sig-
nificantly, single-nucleotide polymorphism (SNP) pro-
filing of primary ALCL tissues has revealed strikingly
higher levels of genomic instability in ALCL ALK− as
compared to ALCL ALK+. This was reflected in p53
loss as a result of the 17p13.3-p12 lesion in 42% of
ALCL ALK− compared to only 9% of ALCL ALK+
patients, and in keeping with the negative regulation
of p53 by NPM–ALK [25]. The second most common
deletion was 6q21 (56% versus 6% in ALCL ALK− ver-
sus ALK+, respectively), resulting in deletion of the B
cell differentiation factor BLIMP1, which is known to
be disrupted in many cases of activated B cells, such
as diffuse large B cell lymphoma [26]. Analysis of
the transcriptome has also been informative, in partic-
ular a recent study comprising 372 peripheral T cell
lymphoma (PTCL) patients, including 31 ALCL ALK+
and 32 ALCL ALK− patient samples, that identified
29 genes that differentiated ALCL ALK+ from ALCL
ALK−, although the overall molecular profile was simi-
lar between the two ALCL sub-entities [27]. At the level
of non-coding RNAs, the miR-17-92 cluster is more
highly expressed in ALCL ALK+, whereas miR-155
is elevated in ALCL ALK− [28]. The latter has been
corroborated by a recent study that used RNA-ISH to
detect miR-155 in ALCL specimens and, in addition,
found colocalization with neoplastic lymphoma cells
[29]. Moreover, ALK regulation of the miR-17-92 clus-
ter, and its ability to partially rescue STAT3 knockdown
in ALCL engraftment models, has been reported [30].
The function of miR-155 in ALCL ALK− and other
mature T cell lymphomas remains unexplored, but it is
known that miR-155 is essential for T cell differentiation
and immunity. Moreover, microRNA-155 was the first
microRNA (miRNA) to be shown to cause lymphoma
in mouse models in two independent studies [31,32].
In this paper, we propose miR-155 as a tumour driver
in the majority of ALCL ALK− cases and demonstrate
its functions in ALCL cell lines. We show active reg-
ulation of interleukin production by miR-155 and that
inhibition of miR-155 leads to reduced growth of ALCL
ALK− tumours in murine engraftment models.
Materials and methods
Cell lines and primary tumour tissues
Formalin-fixed, paraffin-embedded (FFPE) tumours
were kindly provided by the Institute of Clinical Pathol-
ogy at the Medical University of Vienna, after receipt
of informed patient consent and in accordance with
the Declaration of Helsinki. miRNAs were isolated
from 3–5 μm-thick sections, using the RNeasy Mini
Kit (Qiagen) according to the manufacturer’s instruc-
tions. RNA from FFPE lymph nodes from nine healthy
age-matched controls was used as reference material.
ALCL cell lines containing the ALK translocation
SR786 (DSMZ No. ACC 369), SU-DHL-1 (DSMZ
No. ACC 356), SUP-M2 (DSMZ No. ACC 509) and
Karpas-299 (DSMZ No. ACC 31), as well as the T cell
lymphoma cell line JURKAT (DSMZ No. ACC 282),
were obtained from the German Centre for Strains and
Media (DSMZ, Braunschweig, Germany). Cell lines
were gratefully obtained from Marshall Kadin, USA
(Mac1 and Mac2a) and Annarosa del Mistro, Padua,
Italy (FE-PD). Cell proliferation was measured using
the cell titre glow assay (Promega), according to the
manufacturer’s instructions. Chemiluminescence was
assessed using the Infiniti 200 Tecan Reader (Salzburg,
Austria).
Western blotting
For western blots, cell pellets frozen at −80 ∘C were
lysed in RIPA buffer and 30 μg protein/lane was sub-
jected to sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE). Proteins were transferred
to a PVDF membrane and probed with primary antibod-
ies against C/EBPβ (LAP) no. 3087, SHIP1 (C15C9) no.
2725, PTEN no. 9552, Cyclophilin A no. 2175, PTEN
no. 9552 and SOCS1 (A156) no. 3950 (all from Cell
Signaling Technologies, Danvers, MA, USA), followed
by the appropriate horseradish peroxidase-conjugated
anti-mouse or anti-rabbit secondary antibodies
(Amersham Life Science) for 1 h. Enhanced chemi-
luminescence detection was performed according to the
manufacturer’s instructions (Amersham Life Science).
Ago2 immunoprecipitation
Ago2 immunoprecipitation (Ago2 IP) was performed
in three biological replicates, as described [33], with
minor modifications as outlined in Supplementary mate-
rials andmethods (see supplementarymaterial). Overall,
three fractions of RNAwere isolated from IgG1 IP (IgG)
and Ago2 IP (Ago2), as well as total lysate (TL), for fur-
ther analysis. 300 ng each of TL, IgG and Ago2 RNA
was reverse-transcribed and quantified using the Taq-
Man Array system v. 3 (Applied Biosystems), accord-
ing to the manufacturer’s protocol. A list of detected
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miRNAs, including CT values of the three individual
experiments and their relative enrichment in the precip-
itation process, is given in Table S1 (see supplementary
material).
miRNA quantification
Quantitative reverse transcription polymerase chain
reaction (qRT–PCR) of miRNAs was performed using
RNA isolated by miRNeasy or miRNeasy FFPE kits
(Qiagen). For experiments in which individual miRNAs
were monitored, relative amounts of miRNA were
calculated in relation to miR-92, which was stable in all
samples analysed.
Promoter methylation analysis
Briefly, 500 ng–1 μg genomicDNAwas converted using
sodium bisulphite and the EZ DNA Methylation kit
(ZymoResearch). Subsequently, regions of interest were
amplified by PCR (for primer sequences, see supple-
mentary material, Table S2), in vitro transcribed and
base-specifically cleaved by RNase A. Cleavage prod-
ucts were subjected to MALDI–TOF mass spectromet-
ric analysis. Methylation standards were included to
ensure a full dynamic range of measurements. The anal-
ysed regions (14, 15, 16, 18; primers in Table S2) were
chosen to cover the miR-155 promoter CpG island and
the adjacent regulatory regions [34].
MicroRNA transfection
Cells (2.5× 105) were transfected with miRNA mimics
(pre-miR-155, PM12601, anti-miR-155, AM12601;
Ambion) or negative control oligonucleotides using
Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions. The final concentrations of
anti-miR-155 and the miRNA mimic in the transfection
mix were 250 and 50 nM, respectively. Transfection
efficiency was validated by qPCR.
ELISA
For ELISA, the ELISA Ready-Set-Go! Coat-It-Yourself
kit (eBioscience) was used according to the manufac-
turer’s manual. In short, wells of a 96-well plate were
coated with capture antibody (IL-22, clone 22 URTI; or
IL-8, clone 8 CH), washed, blocked and incubated with
the samples and standards (eBioscience). After a sub-
sequent wash step, the wells were incubated with the
detection antibody, which is conjugated to biotin; the
HRP detection enzyme binds to biotin via its conjugated
avidin. After addition of the substrate solution, the plate
was measured with a 680XR ELISA reader (BioRad) in
the linear phase at 450 nm.
Murine xenografts
A murine xenograft model was established by injecting
5× 106 Mac1 or Mac2a cells into the right flank
of non-obese diabetic (NOD) severe combined
immunodeficient (SCID) mice, aged 6 weeks [35].
Injected cell lines had been treated with antisense
miRNA mimics, control RNA, pre-miRNA mimics for
miR-155 (Ambion) and cultured for 3 days to achieve
complete knockdown. miR-155 re-introduction or
down-regulation was verified on the day of injection
by qRT–PCR. Visible tumours developed at days 21
and 40 for the Mac1 and Mac2a cell lines, respectively,
then the mice were killed, the tumours excised and the
sizes and weights of the tumours determined. Xenograft
studies were performed with approval of the local ethics
committee.
Immunohistochemical staining
Tissue samples were fixed in 4% paraformalde-
hyde, embedded in paraffin wax and 2 μm sections
were prepared. The sections were dewaxed and a
steamer pretreatment in Tris–EDTA buffer (Dako)
was performed. Endogenous peroxidase activity was
quenched by incubation in 3% hydrogen peroxide in
phosphate-buffered saline (PBS). For blocking steps,
avidin (Sigma-Aldrich), biotin (Sigma-Aldrich) in PBS,
and a super block (IDlabs Biotechnology) were used.
PY-STAT3 (Cell Signaling, no. 9145), C/EBPβ (sc-150)
and SOCS1 (sc-9021; both Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) were incubated at 4 ∘C
overnight. Immunohistochemical (IHC) detection was
performed using the IDetect Super Stain System HRP
(IDlabs Biotechnology). Specific signals were amplified
using 3-amino-9-ethylcarbazole (IDlabs Biotechnol-
ogy) under visual control, followed by counterstaining
with haematoxylin. Quantitative analysis of the staining
was performed using HistoQuestTM software (Tis-
sueGnostics GmbH; www.tissuegnostics.com; Austria)
[36].
Statistical analysis
For group comparison, an unpaired, two-sided Student’s
t-test was used. Unless indicated otherwise, experiments
were performed at least three times and the standard
deviation (SD) of means is depicted in the graphs.
mRNA expression values were calculated using the
2–ΔΔCT) method. Depicted are expression values nor-
malized OD at 260 nm. GAPDH and miR-92 were used
as standards for mRNAs and miRNAs, respectively. For
Ago2 IP experiments, the numbers given in Figure 2 rep-
resent the mean of three independent experiments. CT
values for individual experiments are given in Table S1
(see supplementary material).
Results
miR-155 is over-expressed in ALCL patient tumours
and ALCL cell lines lacking ALK translocations
Employing an independent cohort of ALCL patient
tumours, we show that miR-155 expression is signifi-
cantly higher in ALK− (n= 11) as compared to ALCL
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Figure 1. Expression of miR-155 in ALCL tissue and regulation of
its target proteins C/EBPβ and SHIP1. (A) miR-155 expression in
primary FFPE samples from ALCL patients with (n= 15) and without
(n= 11) the ALK translocation (normalized to healthy human lymph
nodes) as well as in (B) six ALCL cell lines with and without ALK
translocation. miR-92 was used for standardization [28]; error bars
represent mean± SD. (C) miR-155 mimics were transfected into
ALK-positive ALCL cell lines SR786 and Karpas-299: 3 days after
transfection, cells were lysed, subjected to gel electrophoresis and
probed by western blot with antibodies against the miR-155 targets
C/EBPβ, SOCS1 and SHIP1; a representative western blot of three
independent experiments is shown
ALK+ tumours (n= 15, p< 0.001) or normal lymph
node and CD3+ T cells, corroborating our previous
results (Figure 1A) [28]. These data are consistent
with those from ALCL cell lines, whereby miR-155
expression was assessed in three ALK− and three ALK+
ALCL cell lines and CD3-purified primary human T
cells; miR-155 was expressed 7-, 10- and 42-fold higher
in ALK-negative DL-40, Mac1 and Mac2a ALCL cell
lines, respectively, as compared to normal CD3 purified
T cells (Figure 1B). In contrast, the ALCL ALK+
cell lines Karpas-299, SR786 and SUP-M2 expressed
miR-155 at< 5% of the level observed in CD3-purified
T cells. These data are in keeping with the primary
patient tumour data, whereby miR-155 expression
is more prevalent in ALCL ALK− cases. We next
determined whether transfection of ALCL cell lines
expressing low basal miR-155 (SR786, Karpas-299)
with pre-miR-155 is able to actively alter the level of
its target proteins. Following the re-introduction of
miR-155 into these cell lines, we observed a reduction
in expression levels of the miR-155 targets C/EBPβ to
38% and 36%, and SOCS1 to 41% and 42%, of control
levels. For SHIP1 the effect was less clear (Figure 1C).
Next, we examined expression levels of the miR-155
targets C/EBPβ, SOCS1, SHIP1 and FOXO3a in ALCL
cell lines (see supplementary material, Figure S1A).
C/EBPβ, but none of the other proteins, was low in the
ALCL ALK− Mac1 and Mac2a and high in the ALCL
ALK+ K299 and SR786 cell lines.
miR-155 and mRNAs coding for CEBPβ and SOCS1
are part of the Ago2 complex
To elucidate which microRNAs in the context of ALCL
are bound to Ago2, and are thus functional, we per-
formed Ago2 immunoprecipitation (IP) from the Mac2a
cell line. RNA was isolated from the total lysate (TL),
the IgG control IP (IgG) and the Ago2 IP fraction, and
global miRNA profiling was performed using Taq Man
Array qRT–PCR (Figure 2A). In addition, we probed
for mRNA levels of genes with miR-155 binding sites in
their 3′-UTRs (C/EBPβ, SOCS1, SHIP1 and FOXO3a),
as well as controls without (IL-8, IL-22 and GAPDH) in
the Ago2 IP complex. We found significantly enriched
SOCS1 and C/EBPβ mRNA in the Ago2 IP, whereas
Foxo3a and SHIP1 were not enriched, similar to the
controls (Figure 2B). Therefore, we concluded that, in
the context of ALCL, C/EBPβ and SOCS1 are the main
targets of miR-155, consistent with the data presented
in Figure 1C. As expected, we found a strong mean
enrichment of miRNAs in the Ago2 complex, which
was 419-fold compared to IgG IP and 175-fold com-
pared to TL (Figure 2C). This is also reflected in the
numbers of miRNAs above the detection limit in Ago2,
IgG and TL fractions, which were 318, 262 and 253,
respectively (see supplementary material, Figure S1B).
The control small nucleolar RNAs (RNU44, RNU48,U6
snRNAs; yellow dots), but also several miRNAs, were
not strongly enriched (<10-fold, Figure 2C; see also sup-
plementary material, Table S1). Importantly, miR-155
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Figure 2. miR-155 in the Ago2 complex. (A) Schematic of the Ago2 IP experiment: immunoprecipitation of miRNAs binding to the Ago2
protein was performed in the Mac2a cell line and RNA from the total lysate (TL), the IgG control (IgG) and the Ago2 immunoprecipitation
(Ago2) was isolated. (B) Enrichment of mRNAs with miR-155 binding sites in the 3′-UTR (C/EBPβ, SOCS1, SHIP1 and FOXO3a) in the
Ago2 complex compared to mRNAs without (IL-8, IL-22 and GAPDH); the mean level of the latter (dotted line) has been set to 1 for
standardization. (C) Relative enrichment of microRNAs in the Ago2 IP complex: each dot represents a microRNA (blue) and its relative
enrichment compared to the IgG control (y axis) or TL (x axis); red, miR-155; yellow, small nucleolar RNA. (D) miR-155 (red bar) is the most
abundant microRNA in the Ago2 complex, as measured by Taq-Man qRT–PCR
was enriched 79-fold (compared to total lysate; red dot,
Figure 2C) and the most abundant microRNA in the
Ago2 complex, suggesting active regulation of target
proteins (Figure 2D; see also supplementary material,
Table S1).
miR-155 expression is inhibited
by ALK-independent promoter methylation in ALCL
ALK+ cell lines
The methylation status of three regions upstream of the
miR-155 host gene start site (14, 15, 16) correlates with
miR-155 expression levels [34]. Using bisulphite con-
version, RNAse cleavage and MALDI–TOF mass spec-
troscopic analysis, we analysed the methylation status
of these regions in two ALCL ALK− cell lines with
high miR-155 expression levels (Mac1, Mac2a) and
three ALCL ALK+ cell lines with low miR-155 expres-
sion levels (Karpas-299, SR786, SUP-M2). In the Mac1
and Mac2a cell lines, low levels of promoter methy-
lation were present (0–5%), whereas the Karpas-299,
SR786 and SUP-M2 promoters were highly methylated
(70–100%) at all four regions analysed, suggesting that
promoter methylation contributes to miR-155 regulation
in ALCL (Figure 3A).
To test for an active suppressor function for ALK on
miR-155, we inhibited ALK with the small molecule
inhibitor crizotinib in the ALK+ Karpas-299 cell line
and measured growth and miR-155 expression at
three different time points (4, 8 and 24 h). Due to the
delayed effect of ALK inhibition on miR-155 pro-
moter methylation, we also included a 120 h time point
(see supplementary material, Figure S2). Despite the
expected growth-reducing effect of crizotinib, no signif-
icant increase in miR-155 was observed, suggesting no
direct link between ALK kinase activity and miR-155
expression (Figure 3B, C).
Antagonists of miR-155 reduce tumour growth
in murine xenograft models of ALCL ALK−
To study the role of miR-155 in ALCL without ALK
translocation, we used the cutaneous ALCL ALK−
cell line Mac1, which was transfected with either
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Figure 3. Regulation of miR-155. (A) Using the mass-array tech-
nique, we measured promoter DNA methylation in the miR-155
host gene promoter (MIR155HG) CpG island (16) and adjacent reg-
ulatory regions (14, 15, 18); data represent the mean of two biolog-
ical replicates. (B) The ALCL ALK+ cell line Karpas-299 was treated
with the indicated concentrations of crizotinib and proliferation,
represented by intracellular ATP levels, was measured using a cell
titre glow assay at the indicated time points. (C) Using qRT–PCR,
miR-155 levels were assessed 4, 8 and 24 h after crizotinib treat-
ment. For (B, C), data represent the mean of three biological repli-
cates. Error bars represent mean± SD
an antisense miRNA-155 mimic, control RNA or a
pre-miRNA-155 mimic. Efficiency of knock-out and
knock-in was confirmed 2 days later by qRT–PCR (see
supplementary material, Figure S3A). Cells (5× 106
Mac1 cells) were injected subcutaneously under the
right flank of NOD–SCID mice and, after 21 days,
the mice were sacrificed, the tumours excised and
tumour weights determined. Mice that received cells
treated with anti-miR-155 had the smallest detectable
tumours, whereas mice that received pre-miR-155
treated cells had much larger tumours (p= 0.038,
Figure 4A). Mice that received control RNA-transfected
cells had intermediate tumour sizes, which indicates
that miR-155 provides a tumour growth-promoting
function. To corroborate these findings, another ALCL
ALK− cell line, Mac2a, was employed. The experiments
were performed as described above. In this case, the
mice transplanted with anti-miR-155-transfected cells
developed tumours that were only 10% of the size of
tumours in the control group, thus supporting the potent
anti-tumour effect of anti-miR-155 in this ALCL model
system (p= 0.006; Figure 4B). To study more closely
the mechanism by which anti-miR-155 mimetics reduce
tumour growth, we assessed expression of miR-155
and its targets, C/EBPβ and SOCS1, in the murine
tumours. Despite no difference in miR-155 expression
(see supplementary material, Figure S3B), immuno-
histochemical analysis of C/EBPβ and SOCS1 showed
significantly higher expression in tumours obtained
from mice grafted with the anti-miR155-transfected
Mac1 cells (Figure 4C; p< 0.01). Notably, the tumours
obtained from cells transfected with anti-miR-155 dis-
played higher levels of cleaved caspase 3, suggestive of
miR-155-induced cell survival signals, or at least inhi-
bition of apoptosis (see supplementary material, Figure
S4). Since high SOCS1 levels have been described
to suppress pY-STAT3, we looked at the activity of
STAT3 in these tumours. Indeed, pY-STAT3 levels
were highest in the pre-miR-155-transfected group
and low in the control group, suggesting an active
miR-155–SOCS1–pYSTAT3 axis in these tumours
(Figure 4C).
IL-8 and IL-22, but not IL-10 and IL-21, are
expressed in a miR-155-dependent manner in ALCL
Because of the described role of miR-155 in the immune
system, we assumed that miR-155 might modulate the
tumour environment via cytokines [37]. Therefore, we
assessed the effect of miR-155 over-expression on the
expression and secretion of a cytokine subset (IL-8,
IL-10, IL-21 and IL-22) described in ALCL [20,38,39].
When Karpas-299 and SR786 cells were transduced
with pre-miR-155, IL-8 transcript levels were reduced
by 80% in both cell lines (Figure 5A). Similarly, IL-8
protein levels in the growth medium were reduced after
miR-155 transfection in the Karpas-299 cell line (see
supplementary material, Figure S5A). In the SR786
cell line, IL-8 protein levels were below the detection
limit (data not shown). Consistently, basal levels of
IL-8 were low in ALCL ALK− cell lines (which have
high miR-155 expression levels), as compared to ALCL
ALK+ cell lines (with low miR-155 expression; see
supplementary material, Figure S5B).
In contrast, IL-22 transcript levels were induced 3.2-
and 2.2-fold, respectively, following pre-miR155 trans-
fection (Figure 5B), whereas levels of IL-10 and IL-21
were not significantly affected (see supplementarymate-
rial, Figure S5C). To determine steady-state levels, we
monitored IL-22 mRNA in a panel of ALCL cell lines
and correlated it to miR-155 levels (Figure 5C). In par-
allel, we analysed IL-22 protein levels in the growth
medium by ELISA and detected secreted IL-22 pro-
tein in the range 15–85 ng/ml (Figure 5D). The IL-22
receptor under non-neoplastic conditions is exclusively
expressed in non-haematopoietic cells. However, when
we studied its expression in ALCL cell lines, we found
expression of IL-22R in five of seven cell lines, suggest-
ing active IL-22 signalling in these tumours (see supple-
mentary material, Figure S5D).
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Figure 4. Abrogation of miR-155 reduces tumour growth in an ALCL ALK− mouse model. The ALCL ALK− cell lines Mac1 (A) and Mac2a
(B) were transfected with either with anti-miR-155, control-RNA or pre-miR-155 oligonucleotides. Effective knock-down and knock-in
was verified by qRT–PCR (see supplementary material, Figure S3). Cells (5× 105) were injected subcutaneously under the right flank of
NOD/SCID mice; the mice were sacrificed after 21 and 40 days for experiments with Mac1 and Mac2a cell lines, respectively, the tumours
excised and tumour sizes and weights determined; error bars represent mean± SD. (C) C/EBPβ, SOCS1, pY-STAT3 immunohistochemistry
IHC in murine tumours from Mac1 engraftment experiments containing different initial miR-155 levels: tumours were analysed by IHC
(n= 4); magnification=×20; scale bar= 100 μm; arrows, SOCS1 or pY-STAT3 expression in tumour cells. C/EBPβ, SOCS1 and pY-Stat3 IHC
expression levels were quantified using HistoQuestTM software (TissueGnostics) [36]
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 236: 445–456
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Figure 5. miR-155 influences cytokine expression in ALCL. ALCL ALK+ cell lines Karpas-299 and SR786 were transfected with
pre-miR155-mimics (+) or non-targeting control RNA (−). After 3 days, RNA was isolated, reverse-transcribed and IL-8 (A) and IL-22
(B) transcript levels were measured; data represent mean and SD of three replicates and are representative of two experimental repeats.
(C) RNA was isolated and reverse-transcribed from four ALCL cell lines, and IL-22 and miR-155 levels were determined by qRT–PCR. (D)
Basal levels of IL-22 protein were measured by ELISA with growth media of four ALCL cell lines. (E, F) Blood samples were collected at the
time of tumour excision from the mice described in Figure 3; serum IL-22 levels were determined from mice engrafted with (E) Mac1 and
(F) Mac2a cell lines, by ELISA; error bars represent mean± SD
In addition, IL-22 levels in the serum of mice grafted
with Mac1 cells transfected with anti-miR155 were
significantly lower compared to mice grafted with the
pre-miR155 transfected cells (p= 0.037, Figure 5E).
Consistent with this finding, mice carrying the Mac2a
cells transfected with anti-miR-155 also had sig-
nificantly lower IL-22 levels than the control mice
(p= 0.002, Figure 5F). These data suggest that IL-22
is a miR-155-modulated tumour growth-associated
cytokine in ALCL.
miR-155 targets in primary ALCL tissue
To investigate the relevance of our data, we determined
miR-155, C/EBPβ, SOCS1 and pY-STAT3 in 11 human
ALCL primary patient tissue samples. We showed
high miR-155 expression in four of five ALK− and
low miR-155 expression levels in six of six ALK+
samples (Figure 6A). In all cases analysed, we could
see an inverse correlation of miR-155 with C/EBPβ and
SOCS1 (Figure 6A, B). Interestingly, patient 5, who had
unusually low miR-155 expression for an ALCL ALK−
case, displayed enhanced SOCS1 and C/EBPβ expres-
sion, in line with our observed regulation of these genes
by miR-155. In four of five ALCL ALK− cases, we
could see an inverse correlation of SOCS1 to pY-STAT3,
which suggests that miR-155 suppresses STAT3 acti-
vation via SOCS1 in a significant subgroup of ALCL
ALK− cases. We also assessed SOCS1 and C/EBPβ in
a significant number of primary FFPE ALCL samples.
Both proteins were expressed at significantly lower
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Figure 6. miR-155 targets SOCS1 and C/EBPβ in primary human tumour material. (A) C/EBPβ, SOCS1 and pY-STAT3 were assessed by IHC
and miR-155 by qRT–PCR in 11 human ALCL primary tissue samples; PAT, patient. (B) SOCS1 and C/EBPβ IHC levels were assessed in 36
and 27 FFPE ALCL tissue specimens, respectively, with (red) and without (green) the ALK translocation. (C) Representative IHC pictures
of patient 8 (ALK+), patient 1 (ALK−) and patient 2 (ALK−) are shown; magnification=×20. (D) Schematic drawing depicting our current
view of miR-155 as an inducer of IL-22 and, at the same time, a negative regulator of C/EBPβ and SOCS1. SOCS1 suppression may lead to
pY-STAT3 activation in a significant subset of ALCL ALK− patients
levels in ALCL ALK− compared to ALCL ALK+
patient samples. Figure 6C depicts representative
IHC images from patients 8, 1 and 2. In summary
(Figure 6D), we propose that in ALCL ALK− cells
miR-155 suppresses its direct targets SOCS1 and
C/EBPβ and induces IL-22. This leads to pY-STAT3
activation in a significant sub-fraction of the patients.
Discussion
We have unravelled the functional consequences of
the differential miRNA expression observed in ALCL
ALK− versus ALCL ALK+ tumour cells. In particu-
lar, miR-155 is expressed nine-fold higher in ALCL
ALK− as compared to ALCL ALK+ cells. Analysing
potential miR-155 target proteins in ALCL, we found
that C/EBPβ and SOCS1 are suppressed upon miR-155
re-introduction in ALCL ALK+ cell lines. C/EBPβ lev-
els correlated inversely with miR-155 expression in
ALCL cell lines. In primary patient tissue it has been
shown at both mRNA and protein levels that C/EBPβ is
expressed at significantly lower levels in ALCL ALK−
as compared to ALCL ALK+, which corroborates our
data [20]. We extended these findings by also show-
ing suppression of the miR-155 target SOCS1 in ALCL
ALK−.
When we analysed interleukins IL-8, IL-10, IL-21
and IL-22, which have been reported to play a role in
autocrine or paracrine stimulation of ALCL, we found
that IL-8 is reduced and IL-22 is induced by miR-155
over-expression; IL-10 and IL-21 levels remained
unchanged. The functional consequences of miR-155
depletion were demonstrated in ALCL mouse models
that highly expressed miR-155, but not NPM–ALK, in
their tumours. Mac1 or Mac2a ALCL ALK− cell lines
were engrafted into immune-deficient NOD–SCID
mice. Before engraftment, the cells were treated with
an anti-miR-155 mimic, control RNA or pre-miR-155
mimic. Interestingly, tumour growth was directly
related to miR-155 levels in the injected cells. At the
time point when tumours were harvested, miR-155
levels could not be differentiated between the groups,
indicating dilution of miRNA mimics during tumour
growth. In contrast, when we analysed the tumours of
the mice, we found high levels of the miR-155 targets
SOCS1 and C/EBPβ and low pY-STAT3 levels in
anti-miR-155-treated tumours, suggesting long-term
target regulation. In order to elucidate how miR-155
is regulated in ALCL, we analysed DNA methylation
of the promoter of the miR-155 host gene. In all five
ALCL cell lines analysed, promoter methylation was
inversely correlated to expression of miR-155. The
greater genomic instability that has been demonstrated
for ALCL ALK− with high-density SNP arrays is
remarkable, and the most frequent deletion found was
6q21 in 56% of ALCL ALK− cases, encompassing
the PRDM1 gene coding for BLIMP1. Accordingly,
BLMP1 over-expression led to reduced growth and
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apoptosis induction in an ALCL ALK+ cell line. When
BLIMP1-regulated genes were analysed, it was found
that miR-155 and interferon regulatory factor 4 (IRF-4)
are repressed by BLMP1 [26]. So, in a del6q21 situa-
tion as found in 58% of ALCL ALK− cases, BLMP1
loss may contribute to high miR-155 expression in
ALCL ALK–.
In ALCL ALK+, IL-22 was able to stimulate growth,
IL22R1 was expressed and IL-22 blocking antibod-
ies reduced growth of the SUDHL1 cell line [38].
This supports the idea of an important function of
IL-22/IL-22R1 in ALCL. We extended these studies
to ALCL ALK− by showing that high expression of
IL-22R1 and IL-22 can also be found in ALCL ALK−
cell lines. Accordingly, in this study, we demonstrated
that miR-155 is able to induce IL-22 and is expressed
at much higher levels in ALCL ALK− primary tissue
and cell lines (Figure 1A). A recent study has high-
lighted a mechanism by which miR-155 induces IL-22.
miR-155 represses the DNA binding protein JARID2,
which closely interacts with polycomb repressing com-
plex 2 (PRC2) in Th17 cells, thereby leading to dere-
pression of Th17 typical cytokines, such as IL-22 [40].
Indeed, IL-22 is 3.9-fold more highly expressed in
ALCL ALK− versus ALK+, as revealed by transcrip-
tome analysis of primary tissue [41]. In line with our
findings, it was shown that miR-155 knock-out mice
have impaired Th17 polarization, resulting in reduced
levels of IL-22 secretion after stimulation with anti-CD3
antibody [42,43]. In this pathway there are multiple
possibilities for therapeutic intervention, since IL-22R1
heterodimerizes with IL-10R and is known to activate
downstream tyrosine kinases TYK2 and JAK1 [44].
TYK2 has recently been shown to be essential in T cell
acute lymphoblastic leukaemia (T-ALL) primary cells
[45]. A recent publication [46] using integrated genomic
sequencing shows gain-of-function mutations in JAK1,
JAK3 and STAT5B in T cell prolymphocytic leukaemia
(T-PLL), supporting the importance of JAK kinases for
T cell lymphoma growth. Inhibitors of different JAK
kinases and TYK2 are available, but often their speci-
ficity is limited. However, these inhibitors are actively
being developed further and improved by pharmaceuti-
cal companies [47,48].
Deciphering the role of miR-155 in JAK–STAT sig-
nalling in ALCL ALK− may be the basis for the intro-
duction of more targeted therapeutics in mature T cell
lymphomas, which to date have a dire prognosis.
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